RYLAZE® (Asparaginase Erwinia Chrysanthemi (recombinant)-rywn)

The FDA on July 1, 2021 approved RYLAZE® as a component of a multi-agent chemotherapeutic regimen for the treatment of Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma, in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.  RYLAZE® is a product of Jazz Pharmaceuticals.